SCI Pharmtech Inc (TW:4119) — Market Cap & Net Worth
Market Cap & Net Worth: SCI Pharmtech Inc (4119)
SCI Pharmtech Inc (TW:4119) has a market capitalization of $179.98 Million (NT$5.71 Billion) as of May 2, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #16938 globally and #839 in its home market, demonstrating a -0.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SCI Pharmtech Inc's stock price NT$47.80 by its total outstanding shares 119508634 (119.51 Million). Analyse SCI Pharmtech Inc (4119) cash flow conversion to see how efficiently the company converts income to cash.
SCI Pharmtech Inc Market Cap History: 2015 to 2026
SCI Pharmtech Inc's market capitalization history from 2015 to 2026. Data shows change from $295.31 Million to $179.98 Million (-3.09% CAGR).
SCI Pharmtech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SCI Pharmtech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.22x
SCI Pharmtech Inc's market cap is 0.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.64x
SCI Pharmtech Inc's market cap is 0.64 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $295.31 Million | $1.81 Billion | $373.90 Million | 0.16x | 0.79x |
| 2016 | $250.50 Million | $1.90 Billion | $416.95 Million | 0.13x | 0.60x |
| 2017 | $197.39 Million | $1.30 Billion | $190.98 Million | 0.15x | 1.03x |
| 2018 | $248.43 Million | $1.94 Billion | $447.24 Million | 0.13x | 0.56x |
| 2019 | $394.43 Million | $2.36 Billion | $571.10 Million | 0.17x | 0.69x |
| 2020 | $314.07 Million | $2.69 Billion | $360.12 Million | 0.12x | 0.87x |
| 2021 | $315.59 Million | $864.22 Million | $55.70 Million | 0.37x | 5.67x |
| 2022 | $366.31 Million | $899.74 Million | $308.78 Million | 0.41x | 1.19x |
| 2023 | $364.47 Million | $1.20 Billion | $294.72 Million | 0.30x | 1.24x |
| 2024 | $341.13 Million | $1.52 Billion | $534.68 Million | 0.22x | 0.64x |
Competitor Companies of 4119 by Market Capitalization
Companies near SCI Pharmtech Inc in the global market cap rankings as of May 2, 2026.
Key companies related to SCI Pharmtech Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
SCI Pharmtech Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, SCI Pharmtech Inc's market cap moved from $295.31 Million to $ 179.98 Million, with a yearly change of -3.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$179.98 Million | -1.85% |
| 2025 | NT$183.36 Million | -46.25% |
| 2024 | NT$341.13 Million | -6.40% |
| 2023 | NT$364.47 Million | -0.50% |
| 2022 | NT$366.31 Million | +16.07% |
| 2021 | NT$315.59 Million | +0.48% |
| 2020 | NT$314.07 Million | -20.37% |
| 2019 | NT$394.43 Million | +58.77% |
| 2018 | NT$248.43 Million | +25.86% |
| 2017 | NT$197.39 Million | -21.20% |
| 2016 | NT$250.50 Million | -15.18% |
| 2015 | NT$295.31 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of SCI Pharmtech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $179.98 Million USD |
| MoneyControl | $179.98 Million USD |
| MarketWatch | $179.98 Million USD |
| marketcap.company | $179.98 Million USD |
| Reuters | $179.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SCI Pharmtech Inc
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychl… Read more